Kuykendall, Andrew T.
Sun, Libo
Mascarenhas, John
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Wang, Julia
Xia, Qi
Zhu, Eugene
Feller, Faye
Rizo, Aleksandra
Bussolari, Jacqueline
Wan, Ying
Komrokji, Rami
Article History
Received: 15 September 2021
Accepted: 26 September 2021
First Online: 8 October 2021
Declarations
:
: An independent ethics committee/institutional review board (IRB) had given full approval of the protocol, any amendments, and the informed consent forms for MYF2001. IRB approval was obtained for the collection, analysis, and sharing of real-world data.
: Written informed consent was received by each patient (or a legally acceptable representative) before performance of any study-related activity in MYF2001. Patients in the real-world cohort were not consented for this analysis, as the data were derived per retrospective chart review.
: A.T.K.—research support: Prelude, Sierra Oncology, Protagonist; Speakers Bureau: Novartis, Blueprint; advisory boards/honoraria: Celgene/BMS, Abbvie, Pharmaessentia, Novartis, Blueprint, CTI Biopharma, Incyte; J.M.—research support: Incyte, Janssen, CTI Bio, PharmaEssentia, Novartis, Roche, Kartos, Promedior Merck; consultancy: Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, Geron; J.-J.K.—advisory board: Novartis, AOP Orphan, BMS, AbbVie; A.M.V.—advisory board: Novartis, Abbvie, Celgene, Incyte, Blueprint; Fees (lectures): Novartis, Celgene, Takeda, CTI; Y.W., F.F., L.S., A.R.—employment/equity ownership: Geron Corporation; J.W., Q.X., E.Z., J.B.—employment/equity ownership: Janssen Research and Development; R.S.K.—Speakers Bureau: Celgene/BMS, JAZZ, Agios, Abbvie; advisory boards/honoraria: Celgene/BMS, JAZZ, Agios, Abbvie, Novartis.